Richard H Woods

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Low Density Lipoprotein

Decision Making

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

American journal of perinatology

Current drug safety

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Richard H Woods
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)
Richard H Woods
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Richard H Woods
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Richard H Woods
Equitable Representation of Pregnant and Lactating Women in Clinical Research: A Historical Review and Critical Analysis of Proposed Legislation. American journal of perinatology (2024)
Richard H Woods
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Richard H Woods
Equitable Representation of Pregnant and Lactating Women in Clinical Research: A Historical Review and Critical Analysis of Proposed Legislation. American journal of perinatology (2024)
Richard H Woods
Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration. Current drug safety (2023)
Richard H Woods
Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study. Pharmacotherapy 42 (10) (2022)
Richard H Woods
Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). British journal of clinical pharmacology (2022)